Factors associated with initiation of pharmacological therapy and treatment changes in postural orthostatic tachycardia syndrome
- PMID: 38966085
- PMCID: PMC11222644
- DOI: 10.3389/fneur.2024.1411960
Factors associated with initiation of pharmacological therapy and treatment changes in postural orthostatic tachycardia syndrome
Abstract
Purpose: Postural Orthostatic Tachycardia Syndrome (POTS) is a heterogenous disorder of the autonomic nervous system that is often disabling. There are no FDA-approved therapies for the treatment of this condition. While some patients recover with baseline non-pharmacological intervention, others require repeated trials of off-label pharmacological therapies. The reasoning for this variable treatment response is unknown. The purpose of this work is to identify potential factors that are associated with higher odds of starting pharmacotherapy and/or a higher rate of POTS treatment changes.
Methods: Chart review of demographic, disease and treatment descriptions, medical history, and tilt table examinations of 322 POTS patients who were diagnosed between 2018 and 2020 at our tertiary care center was completed. We first identified the most significant factors associated with an increased odds of starting pharmacotherapy using variable selection techniques and logistic regression. We then identified the most significant factors associated with changes in POTS treatment strategies using variable selection techniques and negative binomial regression modeling. A significance level of 0.05 was utilized.
Results: A total of 752 POTS-specific treatment courses were cataloged, and 429 treatment changes were observed. The most cited reason for a change in management was uncontrolled symptoms. History of migraine headaches, reported fatigue, reported palpitations and a previous POTS diagnosis at an outside institution were found to be associated with a higher odds of starting pharmacotherapy for POTS symptoms (Odds Ratio of 2.40, 1.94, 2.62, 2.08, respectively). History of migraine headaches, reported fatigue, and higher heart rate differences on tilt table examination were found to be associated with an increase in the rate of POTS treatment changes (44, 66, 13% increase in incidence rate, respectively), while reported neck pain was associated with a decrease (27% decrease in incidence rate).
Conclusion: Our work identifies important areas of focus in the development of high-quality trials involving both the non-pharmacological and pharmacological treatment of POTS and highlights several characteristics of patients that may be more refractory to both baseline non-pharmacological treatments and current pharmacological treatment strategies.
Keywords: POTS; fatigue; heart rate; management; migraines; neck pain; treatment.
Copyright © 2024 Tidd, Zhang, Cantrell, Nowacki, Singh and Wilson.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Autonomic dysfunction presenting as postural orthostatic tachycardia syndrome in patients with multiple sclerosis.Int J Med Sci. 2010 Mar 11;7(2):62-7. doi: 10.7150/ijms.7.62. Int J Med Sci. 2010. PMID: 20309394 Free PMC article.
-
Pediatric-Onset Postural Orthostatic Tachycardia Syndrome in a Single Tertiary Care Center.J Child Neurol. 2020 Jul;35(8):526-535. doi: 10.1177/0883073820916260. Epub 2020 Apr 21. J Child Neurol. 2020. PMID: 32314650
-
Comorbidity of postural orthostatic tachycardia syndrome and chronic fatigue syndrome in an Australian cohort.J Intern Med. 2014 Apr;275(4):409-17. doi: 10.1111/joim.12161. Epub 2013 Nov 29. J Intern Med. 2014. PMID: 24206536
-
Pharmacotherapy for postural tachycardia syndrome.Auton Neurosci. 2018 Dec;215:28-36. doi: 10.1016/j.autneu.2018.04.008. Epub 2018 May 4. Auton Neurosci. 2018. PMID: 29753556 Review.
-
Novel pharmacotherapeutic options for the treatment of postural orthostatic tachycardia syndrome.Expert Opin Pharmacother. 2024 Feb;25(2):181-188. doi: 10.1080/14656566.2024.2319224. Epub 2024 Mar 11. Expert Opin Pharmacother. 2024. PMID: 38465412 Review.
Cited by
-
Corneal Confocal Microscopy in Postural Orthostatic Tachycardia Syndrome (POTS) as a Diagnostic Tool for Small Fiber Neuropathy.Cureus. 2025 Apr 22;17(4):e82781. doi: 10.7759/cureus.82781. eCollection 2025 Apr. Cureus. 2025. PMID: 40271232 Free PMC article.
-
Long-COVID and postural orthostatic tachycardia syndrome: a preliminary comparison of neuropsychological performance.Clin Auton Res. 2025 Apr;35(2):285-299. doi: 10.1007/s10286-025-01106-y. Epub 2025 Jan 22. Clin Auton Res. 2025. PMID: 39838139 Free PMC article.
References
-
- Vernino S, Bourne KM, Stiles LE, Grubb BP, Fedorowski A, Stewart JM, et al. . Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health expert consensus meeting - part 1. Auton Neurosci. (2021) 235:102828. doi: 10.1016/j.autneu.2021.102828, PMID: - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources